SC
AVXL icon

Sculptor Capital’s Anavex Life Sciences AVXL Stock Holding History

Sculptor Capital’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-155,900
Closed -$555K – 376
2025
Q4 		$555K Hold
155,900
– – 0.01% 295
2025
Q3 		$1.39M Hold
155,900
– – 0.02% 241
2025
Q2 		$1.44M Buy
+155,900
New +$1.33M 0.02% 232
2025
Q1 		– Sell
-370,100
Closed -$3.97M – 333
2024
Q4 		$3.97M Sell
370,100
-300
-0.1% -$2.31K 0.05% 166
2024
Q3 		$2.1M Hold
370,400
– – 0.04% 171
2024
Q2 		$1.56M Hold
370,400
– – 0.03% 151
2024
Q1 		$1.89M Buy
+370,400
New +$2.08M 0.04% 140

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Sculptor Capital's AVXL Position: Q1 2026 in Review

Sculptor Capital sold out of Anavex Life Sciences (AVXL) in Q1 2026, closing a stake of 155,900 shares — an estimated $555K sold.

Sculptor Capital first reported a position in AVXL in Q1 2024 and held it in 7 quarters. The position peaked at $3.97M in Q4 2024. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Sculptor Capital reported no remaining Anavex Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Sculptor Capital sold 155,900 Anavex Life Sciences shares in Q1 2026, an estimated $555K.
  • Sculptor Capital first reported a position in Anavex Life Sciences in Q1 2024 and held it in 7 quarters.
  • Sculptor Capital's Anavex Life Sciences position peaked at $3.97M in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Sculptor Capital's 13F filing for Q1 2026, filed 15 May 2026.